Sigfrid, Louise 
ORCID: 0000-0003-2764-1177, Cevik, Muge ORCID: 0000-0003-1133-3874, Jesudason, Edwin, Lim, Wei Shen, Rello, Jordi ORCID: 0000-0003-0676-6210, Amuasi, John Humphrey, Bozza, Fernando ORCID: 0000-0003-4878-0256, Palmieri, Carlo ORCID: 0000-0001-9496-2718, Munblit, Daniel ORCID: 0000-0001-9652-6856, Holter, Jan Cato ORCID: 0000-0003-1618-5022 et al (show 26 more authors)
(2020)
What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study.
MedRxiv.
2020.08.26.20180950-.
Abstract
<h4>Introduction: </h4> Very little is known about possible clinical sequelae that may persist after resolution of the acute Coronavirus Disease 2019 (COVID-19). A recent longitudinal cohort from Italy including 143 patients recovered after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60 day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. Methods and analysis This is an international open-access prospective, observational multi-site study. It will enrol patients following a diagnosis of COVID-19. Tier 1 is developed for following up patients day 28 post-discharge, additionally at 3 to 6 months intervals. This module can be used to identify sub-sets of patients experiencing specific symptomatology or syndromes for further follow up. A Tier 2 module will be developed for in-clinic, in-depth follow up. The primary aim is to characterise physical consequences in patients post-COVID-19. Secondary aim includes estimating the frequency of and risk factors for post-COVID- 19 medical sequalae, psychosocial consequences and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer term antibody, innate and cell-mediated immune responses to SARS-CoV-2. Ethics and dissemination This collaborative, open-access study aims to characterize the frequency of and risk factors for long-term consequences and characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardized and longitudinal data collection globally. The outcomes of this study will inform strategies to prevent long term consequences; inform clinical management, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Infectious Diseases, Biodefense, Cancer, Vaccine Related, Emerging Infectious Diseases, Prevention, Clinical Research, Behavioral and Social Science, 2 Aetiology, 2.4 Surveillance and distribution, Generic health relevance, 3 Good Health and Well Being |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 08 Jan 2021 15:32 |
| Last Modified: | 14 Mar 2024 20:33 |
| DOI: | 10.1101/2020.08.26.20180950 |
| Open Access URL: | https://doi.org/10.1101/2020.08.26.20180950 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3112068 |
Dimensions
Dimensions
